| FLORIDA BIOLOGIX® ANNOUNCES MANUFACTURING AGREEMENT WITH AMERICA STEM CELL, INC.
ALACHUA, FL, SEPTEMBER 21, 2009. America Stem Cell, Inc. (ASC) and Florida Biologix team up to get an important cancer therapy to the clinic that can potentially making a life-changing difference for patients with blood-related cancers such as Leukemia, Lymphoma and Myeloma.... Learn more...
----------------------------------------------------------
AMERICA STEM CELL, INC. AWARDED $2.5 MILLION FROM THE TEXAS EMERGING TECHNOLOGY FUND
SAN ANTONIO, TX, JULY 15, 2009 11:00 A.M. (CST). America Stem Cell, Inc. (ASC) announced today that the company has been awarded $2.5 million from the State of Texas Emerging Technology Fund ("ETF")... Learn more...
----------------------------------------------------------
BLOMBERG BUSINESS NEWS
America Stem Cell, Inc., a biotechnology company, develops and commercializes stem cell technologies. Its products include ASC-101, which is a human recombinant enzyme technology that increases the efficiency of engraftment in transplantation of cord blood derived stem cells ...read more
----------------------------------------------------------
STEM CELL ENABLING TECHNOLOGIES UNVEILED AT CORD BLOOD TRANSPLANTATION MEETING IN LA
Los Angeles, CA (PRWEB) June 04, 2008
America Stem Cell, Inc. announced today that exciting pre-clinical data on two of their breakthrough enabling technologies -Engraftin™ and its ensuing product, a CD26 Inhibitor - will be presented at the 6th Annual International Umbilical Cord Blood Transplantation Symposium, June 6-7 in Los Angeles. America Stem Cell is developing both technologies to enhance and expand the therapeutic potential of stem cells in bone marrow transplants for improved patient survival and quality of life.
Contact: Amelia Spiliotes, Executive Vice President, Corporate Development, Tel: (617) 306-3278 www.americastemcell.com # # #
posted on http://www.prweb.com/releases/stem_cell/Bone_marow/prweb991964.htm
----------------------------------------------------------
DARA BIOSCIENCES AND AMERICA STEM CELL BROADEN COLLABORATION
RALEIGH, N.C., Oct. 12, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a development-stage biopharmaceutical company, announced today that the Company has entered into an Addendum and First Amendment to Material Transfer Agreement with America Stem Cell, Inc. (ASC), pursuant to which the Material Transfer Agreement between the Company and ASC dated March 24, 2008 was amended. Under the Material Transfer Agreement, the Company is providing ASC with dipeptidylpeptidase (DPPIV) inhibitors from its proprietary library which ASC is using to further its research and development program related to hematopoietic stem cell (HSC) transplants... Learn More ...
----------------------------------------------------------
America Stem Cell Inc Awarded “Most Promising Life Science Technology Company” at Rice Alliance Life Science Venture Forum
HOUSTON
– September 3, 2010 – America Stem Cell Inc, was named
the ‘Most Promising’ Life Science company at the 9th Annual Rice Alliance for
Technology & Entrepreneurship Life Science Venture Forum in Houston last
week. Life Science companies showcased their new ventures for an audience of
more than 400 attendees, including investors, venture capitalists, industry
representatives, business leaders, advisors/mentors, service providers, and
entrepreneurs.
Cynthia A. Doerr, M.D., partner, Essex Woodlands Health Ventures
said of the presenters, “This is one of the most mature groups of
healthcare-related company presentations that I have reviewed in Houston, and I
intend to follow their progress closely.”
America Stem Cell Inc (ASC) is
developing and commercializing breakthrough patented products to enable
successful stem cell therapy outcomes, initially for transforming survival and
quality of life of patients undergoing stem cell transplantation for cancer.
Its lead clinical candidate, ASC-101, is a patented enzymatic, ex vivo treatment of stem cells that
accelerates the rate and extent of stem cell homing to and engraftment within
targeted diseased organs. Preclinical proof of principle data show a 4-5 times (400
– 500%) improvement in the rate and extent of stem cell homing and engraftment.
America Stem Cell expects to
file an IND for ASC-101 this year.
The Company plans to begin a Phase I/II trial at University of Texas MD
Anderson Cancer Center in early 2011 and is initiating a $10M Series B round to
fund the clinical program through human proof-of-concept, a milestone that it
believes will significantly increase shareholder value. America Stem Cell is also developing
ASC-201, a small molecule that improves engraftment by another mechanism that is
expected to be additive to ASC-101.
Lynnet Koh-LeMaire, CEO/Founder said ‘America
Stem Cell Inc is poised to transform the survival and quality of life of cancer
patients undergoing stem cell transplantation for treatment of blood-related
cancers. We are also well positioned to transform clinical outcomes for
patients undergoing stem cell therapy to treat various other diseases such as
diabetes, cardiovascular and neural diseases as well as wound healing,
cartilage, muscle and bone regeneration.
We are honored to be selected as the‘Most
Promising’ Life Science company by the Rice University Venture Forum’.
The one-day event culminated in an announcement of the Most
Promising Life Science Companies chosen from nearly 40 competitors and
judged by the Rice Alliance Information Technology Advisory Board, based on the
companies’ elevator pitch presentations. The exercise simulates meeting an
investor on an elevator and having only 90 seconds to convince them to invest
in your company.
In addition, five other new life science technology companies were
pre-selected to present their 10-minute business plan presentation at the
forum, and as one of the chosen five, were also named a Most Promising Life Science
Technology Company.
Rice Alliance Director Brad Burke, announced the winners of the
Most Promising Life Science Company awards at the event. “Every year the
quality of companies improves. Many of the companies at this year’s event have
developed prototypes, obtained proven results and are on their second round of
funding. This makes them more appealing to investors, who have also expressed
appreciation for the quality of the companies.”
The Forum was supported by Baker Botts, LLP, Essex Woodlands
Health Ventures, Winstead Attorneys and Santé Venture with supporting
sponsors Greater Houston Partnership
and Houston Technology Center and
media sponsors Houston Business Journal and the BusinessMakers Radio
Show. Elevator pitches from the competition can be seen at www.alliance.rice.edu beginning July 6,
2010.
###
----------------------------------------------------------
AMERICA STEM CELL, INC. RECEIVES ORPHAN DRUG DESIGNATION FOR ASC-101
Novel enabling technology
to enhance stem cell treatments for cancer patients
Orphan designation
provides seven–year post approval marketing exclusivity, tax credits, and
elimination of FDA prescription drug user fees
sAN
ANTONIO, Mar.
29, 2011. America Stem Cell, Inc. announced today that the
U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to
ASC-101 to improve homing to bone marrow (treatment of myeloablation) in
patients receiving hematopoietic stem cell transplantation.
“The
orphan drug status confirms the importance of this new novel treatment approach
to improve outcomes for patients with serious, life-threatening cancers and
other disorders for which hematopoietic stem cell transplant is prescribed,”
said Dr. Linda J. Paradiso, Chief Development Officer at America Stem Cell.
ASC-101 will potentially transform hematopoietic stem cell transplantation by accelerating
patients’ immune system and platelet recovery, reducing opportunistic
infections and other co-morbidities, and possibly improving patient survival.
The FDA orphan
drug designation will confer America Stem financial benefits and incentives,
such as potential Orphan Drug grant funding to defray the cost of clinical
testing, tax credits for the costs of clinical research, seven–year period of
exclusive marketing after approval and Waiver of Prescription Drug User Fee Act
(PDUFA) filing fees.
“This
recognition of orphan drug status for ASC-101 by the FDA together with a strong
proprietary intellectual property portfolio, positive preclinical proof of
principle data and our completion of GLP toxicology and cGMP clinical product
manufacturing points to the strong potential for America Stem Cell to transform
clinical outcomes for these advanced cancer patients,” said Lynnet Koh,
Founder, CEO and Chairman of the Board of America Stem Cell.
America
Stem Cell is poised to commence a Phase I/IIa clinical trial for the treatment
of advanced hematological cancers at the University of Texas MD Anderson Cancer
Center in Houston.
###
----------------------------------------------------------
|
